GV20 0251
Alternative Names: GV20-0251Latest Information Update: 20 Sep 2024
At a glance
- Originator GV20 Oncotherapy
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; IGSF8 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Clinical Phase Unknown Cancer
Most Recent Events
- 16 Sep 2024 Clinical trials in Cancer (Second-line therapy or greater, Combination therapy) (Parenteral)
- 16 Sep 2024 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Solid tumours released by GV20 Oncotherapy
- 18 Apr 2024 GV20 Therapeutics entered into clinical collaboration and supply agreement with Merck for the advanced development of GV20 0251